Nitin Dilip Joshi, MD
Hematology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 13
- 3 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Eden Medical Center · Stanford Health Care · Stanford Health Care Tri-Valley · Washington Hospital. That is not proof they admit you there this week.
Plans that list them
13 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Joshi’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
13 of 13 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A93287 · Current
Licensed to practise in California · since 2005 · expires 2027-11-30 · South Gujarat University, Government Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
State licence records
1 licence
- New Jersey 25MA08210300Medical Doctor · since 2007 · expires 2011-06-30InactiveNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
Hospitals they work in
4 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Eden Medical CenterCastro Valley, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 75% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.122, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
- Washington HospitalFremont, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of Washington Hospital Healthcare SystemPatients rate it 3 of 5 · 71% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.188, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.164, Oct 2024 – Sep 2025
See every measure and the patient survey for Eden Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 7 the same, 0 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.122 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.88 (0 to 1.89) · 819 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.46 to 1.16) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 137.41 (92.94 to 181.88) · 70 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.4 · 78 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.7 · 38 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.1 · 207 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.6 · 359 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.5 · 355 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 1,714 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.17 (0 to 0.39) · 4,697 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.3 (0.1 to 0.5) · 4,676 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.69 (0.53 to 4.85) · 860 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.56 (0 to 3.24) · 251 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.75 (1.17 to 4.32) · 818 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.76 (0 to 15.78) · 261 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.09 (2.08 to 10.1) · 242 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.64 (0.16 to 3.12) · 233 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.85) · 4,132 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.9 · 60 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.431 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.292 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.307 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.61 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 258 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 22.6 · 225 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 2.4 · 367 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.9 · 390 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 58 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 88 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.9 (9.6 to 17.4) · 68 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.1) · 205 cases | No different | Jan 2024 – Dec 2024 |
What patients said (431 patients answered, 17% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 58% |
| "YES", patients would definitely recommend the hospital | 75% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
See every measure and the patient survey for Washington Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 1 better, 6 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.188 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.164 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.88 (0 to 1.88) · 1,112 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.92 (0.59 to 1.24) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 192.95 (139.54 to 246.36) · 48 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2 · 27 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.4 · 164 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.1 · 199 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 463 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 661 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.3 · 174 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.7 · 2,550 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.15 (0 to 0.35) · 6,970 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,108 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.82 (1.73 to 5.91) · 1,370 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.52 (0 to 3.17) · 589 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.75 (0.25 to 3.25) · 1,315 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 13.19 (5.83 to 20.56) · 600 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.91 (1.04 to 8.78) · 550 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.66 (0.17 to 3.14) · 198 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 6,079 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 114 cases | None | Apr 2023 – Mar 2025 |
| MRSA BacteremiaInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.367 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.8 · 186 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.9 · 480 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 33.9 · 186 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 26.5 · 553 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 36.8 · 648 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.5 · 590 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.7 (3.2 to 6.9) · 169 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.4 (8.5 to 14.9) · 169 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 130 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.1 · 41 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 202 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.7 (10.2 to 18.5) · 78 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.1) · 974 cases | No different | Jan 2024 – Dec 2024 |
What patients said (812 patients answered, 19% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 84% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 71% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 72% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 46% |
| "YES", patients would definitely recommend the hospital | 71% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 84% |
Original Medicare doctor bills
$636,510
Medicare paid this office $636,510 for 737 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 512 | $135,342 | $113 |
| Long return visit (40+ min) | 122 | $34,373 | $164 |
| Short return visit (20+ min) | 233 | $25,733 | $78 |
| New patient visit (60+ min) | 91 | $17,592 | $193 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 67 | $16,663 | $105 |
See all 30 services
| Return visit (30+ min) | 512 | $135,342 | $113 |
| Long return visit (40+ min) | 122 | $34,373 | $164 |
| Short return visit (20+ min) | 233 | $25,733 | $78 |
| New patient visit (60+ min) | 91 | $17,592 | $193 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 67 | $16,663 | $105 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 15 | $12,902 | None |
| Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 14 | $10,642 | None |
| Administration of chemotherapy into vein, 1 hour or less | 39 | $9,457 | $137 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 226 | $6,197 | $15 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 38 | $5,972 | $153 |
| Drawing of blood for a medical problem | 33 | $5,929 | $99 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 32 | $5,291 | $115 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 44 | $4,388 | $70 |
| New patient visit (45+ min) | 24 | $3,299 | $137 |
| Insertion of needle into vein for collection of blood sample | 257 | $3,287 | $9 |
| Irrigation of implanted venous access drug delivery device | 40 | $2,798 | $27 |
| Administration of additional new drug or substance into vein, 1 hour or less | 19 | $2,635 | $68 |
| Injection of additional new drug or substance into vein | 43 | $2,615 | $16 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 154 | $1,726 | $8 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 12 | $1,396 | $63 |
| Administration of chemotherapy into vein, each additional hour | 12 | $912 | $28 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 16 | $707 | $29 |
| Injection of drug or substance under skin or into muscle | 28 | $694 | $13 |
| Telephone medical discussion with physician, 5-10 minutes | 11 | $608 | $55 |
| Injection, carboplatin, 50 mg | 12 | $411 | None |
| Application of on-body injector for under skin injection | 14 | $315 | $19 |
| Injection, palonosetron hcl, 25 mcg | 16 | $157 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 37 | $72 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 25 | $27 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 14 | $16 | None |
Who their Medicare patients are
737 Original Medicare patients in 2024. Average age 75 · Under 65 7% · 85 and older 16% · Women 62% · Also on Medicaid 30% · Health risk score 1.74. At or below the middle of the specialty; the typical hematology clinician is at 2.35.
Conditions among them: High blood pressure 75% · Cancer 43% · Diabetes 40% · Chronic kidney disease 39% · Coronary heart disease 28% · Heart failure 21% · Depression 21% · Atrial fibrillation 20% · COPD 19% · Stroke 12% · Dementia 9%.
The office billed $3,851,473, Medicare allowed $818,832 and paid $636,510; for 38,589 services of 91 kinds; $343,814 of it was for drugs given in the office and $292,696 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 737 | 38,589 | 75 | 1.74 | $3,851,473 | $636,510 |
| 2023 | 681 | 68,699 | 75 | 1.85 | $3,533,215 | $786,927 |
| 2022 | 729 | 131,790 | 76 | 1.83 | $4,279,028 | $967,161 |
| 2021 | 798 | 210,257 | 75 | 1.87 | $9,149,108 | $2,089,638 |
| 2020 | 770 | 251,586 | 74 | 2.02 | $15,689,865 | $3,428,806 |
| 2019 | 704 | 222,371 | 74 | 2.13 | $10,055,751 | $2,356,132 |
| 2018 | 671 | 293,479 | 74 | 2.17 | $12,184,423 | $3,011,015 |
| 2017 | 606 | 260,517 | 74 | 2.33 | $9,494,299 | $2,073,879 |
| 2016 | 562 | 330,143 | 75 | 2.25 | $7,803,066 | $2,346,336 |
| 2015 | 510 | 338,244 | 75 | 2.32 | $8,098,226 | $2,656,017 |
| 2014 | 407 | 252,191 | 75 | 2.33 | $5,838,305 | $1,770,026 |
| 2013 | 434 | 163,199 | 74 | 2.55 | $3,978,755 | $1,308,632 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 28 services
| Return visit (30+ min) | 440 | $120,986 | $114 |
| Long return visit (40+ min) | 128 | $36,360 | $163 |
| Short return visit (20+ min) | 261 | $29,892 | $75 |
| Injection, ferric carboxymaltose, 1 mg | 29 | $25,670 | None |
| New patient visit (60+ min) | 84 | $16,885 | $201 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 15 | $14,994 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 56 | $14,805 | $104 |
| Administration of chemotherapy into vein, 1 hour or less | 36 | $11,631 | $138 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 41 | $6,287 | $70 |
| Drawing of blood for a medical problem | 32 | $5,561 | $101 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 31 | $4,920 | $154 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 259 | $4,273 | $8 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 34 | $3,624 | $66 |
| New patient visit (45+ min) | 22 | $3,187 | $145 |
| Injection of additional new drug or substance into vein | 53 | $2,792 | $16 |
| Administration of additional new drug or substance into vein, 1 hour or less | 12 | $2,159 | $67 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 15 | $2,070 | $115 |
| Administration of chemotherapy into vein, each additional hour | 21 | $1,722 | $29 |
| Injection of drug or substance into vein | 33 | $1,535 | $38 |
| Injection of drug or substance under skin or into muscle | 64 | $1,528 | $13 |
| Irrigation of implanted venous access drug delivery device | 28 | $1,308 | $25 |
| Infusion into a vein for hydration, 31-60 minutes | 15 | $812 | $34 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 13 | $598 | $21 |
| Injection, zoledronic acid, 1 mg | 15 | $567 | None |
| Injection, palonosetron hcl, 25 mcg | 14 | $187 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 45 | $80 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 25 | $48 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 18 | $40 | None |
2022: 45 services
| Return visit (30+ min) | 478 | $132,411 | $112 |
| Injection, rituximab, 10 mg | 12 | $86,249 | None |
| Injection, denosumab, 1 mg | 16 | $53,712 | None |
| Long return visit (40+ min) | 151 | $44,073 | $164 |
| Injection, ferric carboxymaltose, 1 mg | 41 | $42,865 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 27 | $29,200 | None |
| Short return visit (20+ min) | 230 | $26,066 | $75 |
| Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 20 | $24,839 | None |
| Administration of chemotherapy into vein, 1 hour or less | 66 | $23,200 | $143 |
| New patient visit (60+ min) | 95 | $18,988 | $200 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 64 | $12,854 | $90 |
| Drawing of blood for a medical problem | 36 | $10,279 | $101 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 12 | $7,624 | $173 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 40 | $7,340 | $175 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 386 | $6,715 | $8 |
| Injection of additional new drug or substance into vein | 91 | $6,316 | $16 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 44 | $5,072 | $69 |
| Administration of additional new drug or substance into vein, 1 hour or less | 30 | $4,329 | $69 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 41 | $4,272 | $63 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 26 | $3,448 | $119 |
| New patient visit (45+ min) | 26 | $3,439 | $132 |
| Administration of additional new drug or substance into vein using push technique | 14 | $2,985 | $60 |
| Telephone medical discussion with physician, 11-20 minutes | 34 | $2,755 | $71 |
| Injection of drug or substance under skin or into muscle | 92 | $2,647 | $13 |
| Administration of chemotherapy into vein, each additional hour | 29 | $2,546 | $29 |
| Injection of drug or substance into vein | 40 | $2,311 | $41 |
| Insertion of needle into vein for collection of blood sample | 331 | $1,746 | $3 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 12 | $1,592 | $34 |
| Irrigation of implanted venous access drug delivery device | 25 | $1,587 | $25 |
| Infusion into a vein for hydration, 31-60 minutes | 21 | $1,284 | $35 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 15 | $995 | $30 |
| Injection, fluorouracil, 500 mg | 13 | $709 | None |
| Infusion into a vein for hydration, each additional hour | 20 | $637 | $13 |
| Telephone medical discussion with physician, 5-10 minutes | 19 | $611 | $32 |
| Injection, palonosetron hcl, 25 mcg | 20 | $483 | None |
| Injection, fosaprepitant, 1 mg | 13 | $481 | None |
| Application of on-body injector for under skin injection | 13 | $438 | $19 |
| Injection, carboplatin, 50 mg | 12 | $281 | None |
| Injection, paclitaxel, 1 mg | 11 | $254 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 85 | $193 | None |
| Infusion, normal saline solution , 1000 cc | 18 | $95 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 42 | $71 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 18 | $54 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 30 | $38 | None |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 16 | $13 | None |
2021: 44 services
| Injection, pembrolizumab, 1 mg | 14 | $205,758 | None |
| Return visit (30+ min) | 467 | $138,537 | $120 |
| Injection, pegfilgrastim, 6 mg | 26 | $132,432 | None |
| Injection, denosumab, 1 mg | 42 | $120,560 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 42 | $84,907 | None |
| Administration of chemotherapy into vein, 1 hour or less | 71 | $44,969 | $153 |
| Injection, ferric carboxymaltose, 1 mg | 42 | $44,532 | None |
| Long return visit (40+ min) | 143 | $40,762 | $169 |
| Short return visit (20+ min) | 309 | $38,307 | $83 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 30 | $24,635 | $1 |
| New patient visit (60+ min) | 93 | $18,492 | $199 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 77 | $18,103 | $94 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 61 | $12,035 | $182 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 72 | $9,282 | $75 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 421 | $9,052 | $8 |
| Injection of additional new drug or substance into vein | 76 | $8,040 | $17 |
| New patient visit (45+ min) | 52 | $7,720 | $148 |
| Drawing of blood for a medical problem | 28 | $6,694 | $108 |
| Telephone medical discussion with physician, 11-20 minutes | 71 | $6,155 | $68 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 46 | $5,967 | $124 |
| Injection of drug or substance under skin or into muscle | 131 | $5,852 | $13 |
| Administration of additional new drug or substance into vein using push technique | 19 | $4,273 | $64 |
| Insertion of needle into vein for collection of blood sample | 493 | $4,245 | $3 |
| Telephone medical discussion with physician, 21-30 minutes | 27 | $4,135 | $125 |
| Administration of additional new drug or substance into vein, 1 hour or less | 22 | $3,980 | $75 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 36 | $3,960 | $66 |
| Injection of drug or substance into vein | 54 | $3,684 | $43 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 16 | $3,178 | $33 |
| Administration of chemotherapy into vein, each additional hour | 28 | $3,099 | $32 |
| Infusion into a vein for hydration, 31-60 minutes | 28 | $1,798 | $37 |
| Irrigation of implanted venous access drug delivery device | 29 | $1,676 | $28 |
| Injection, palonosetron hcl, 25 mcg | 26 | $1,591 | None |
| Injection, zoledronic acid, 1 mg | 18 | $961 | None |
| Infusion into a vein for hydration, each additional hour | 29 | $907 | $14 |
| Application of on-body injector for under skin injection | 20 | $856 | $20 |
| Telephone medical discussion with physician, 5-10 minutes | 13 | $772 | $55 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 11 | $688 | $33 |
| Injection, fluorouracil, 500 mg | 12 | $457 | None |
| Complete blood cell count (red cells, white blood cell, platelets), automated test | 31 | $324 | $6 |
| Injection, dexamethasone sodium phosphate, 1 mg | 71 | $278 | None |
| Infusion, normal saline solution , 1000 cc | 36 | $158 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 31 | $84 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 30 | $83 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 24 | $40 | None |
2020: 45 services
| Injection, pembrolizumab, 1 mg | 13 | $595,276 | None |
| Injection, pegfilgrastim, 6 mg | 26 | $282,790 | None |
| Injection, rituximab, 10 mg | 13 | $205,399 | None |
| Return visit (30+ min) | 530 | $133,431 | $97 |
| Injection, denosumab, 1 mg | 35 | $121,945 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 47 | $99,813 | None |
| Administration of chemotherapy into vein, 1 hour or less | 82 | $76,259 | $148 |
| Injection, ferric carboxymaltose, 1 mg | 55 | $57,331 | None |
| Long return visit (40+ min) | 124 | $23,009 | $135 |
| New patient visit (60+ min) | 119 | $21,813 | $183 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 85 | $21,385 | $95 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 93 | $19,256 | $185 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 19 | $15,481 | $1 |
| Short return visit (20+ min) | 160 | $15,028 | $69 |
| Injection of additional new drug or substance into vein | 95 | $14,177 | $16 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 11 | $10,600 | $171 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 365 | $9,845 | $8 |
| Drawing of blood for a medical problem | 31 | $8,810 | $99 |
| Administration of additional new drug or substance into vein using push technique | 22 | $6,425 | $62 |
| Administration of chemotherapy into vein, each additional hour | 39 | $5,937 | $31 |
| Injection of drug or substance under skin or into muscle | 141 | $5,884 | $13 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 40 | $5,258 | $70 |
| Administration of additional new drug or substance into vein, 1 hour or less | 27 | $5,018 | $72 |
| New patient visit (45+ min) | 32 | $4,762 | $149 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 36 | $4,449 | $66 |
| Injection of drug or substance into vein | 66 | $4,192 | $39 |
| Insertion of needle into vein for collection of blood sample | 418 | $4,164 | $3 |
| Injection, palonosetron hcl, 25 mcg | 22 | $3,178 | None |
| Administration of chemotherapy into vein using push technique | 12 | $3,164 | $113 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 22 | $3,154 | $126 |
| Irrigation of implanted venous access drug delivery device | 38 | $2,238 | $27 |
| Infusion into a vein for hydration, 31-60 minutes | 26 | $1,873 | $35 |
| Application of on-body injector for under skin injection | 20 | $1,107 | $20 |
| Injection, carboplatin, 50 mg | 20 | $1,056 | None |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 11 | $914 | $33 |
| Injection, paclitaxel, 1 mg | 11 | $838 | None |
| Injection, fluorouracil, 500 mg | 11 | $738 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 14 | $637 | $32 |
| Infusion into a vein for hydration, each additional hour | 21 | $579 | $13 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test | 33 | $340 | $6 |
| Injection, dexamethasone sodium phosphate, 1 mg | 89 | $323 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 41 | $148 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 43 | $130 | None |
| Infusion, normal saline solution , 1000 cc | 28 | $124 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 50 | $121 | None |
2019: 42 services
| Injection, denosumab, 1 mg | 58 | $231,368 | None |
| Injection, pegfilgrastim, 6 mg | 19 | $192,798 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 43 | $145,364 | None |
| Injection, rituximab, 10 mg | 11 | $142,570 | None |
| Return visit (30+ min) | 527 | $135,124 | $94 |
| Administration of chemotherapy into vein, 1 hour or less | 63 | $37,358 | $145 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 37 | $27,898 | $1 |
| Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | 15 | $23,738 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 86 | $21,366 | $94 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 98 | $20,892 | $182 |
| Long return visit (40+ min) | 121 | $20,482 | $131 |
| New patient visit (60+ min) | 107 | $19,702 | $184 |
| Injection, ferric carboxymaltose, 1 mg | 16 | $17,874 | None |
| Short return visit (20+ min) | 135 | $14,214 | $69 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 503 | $13,382 | $8 |
| Injection of drug or substance under skin or into muscle | 151 | $9,444 | $16 |
| Injection, palonosetron hcl, 25 mcg | 32 | $9,331 | None |
| Injection of additional new drug or substance into vein | 99 | $8,890 | $17 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 41 | $6,705 | $71 |
| Administration of additional new drug or substance into vein, 1 hour or less | 23 | $6,573 | $70 |
| Drawing of blood for a medical problem | 26 | $6,280 | $103 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 37 | $4,000 | $31 |
| Administration of chemotherapy into vein, each additional hour | 23 | $3,400 | $31 |
| Injection of drug or substance into vein | 45 | $3,011 | $40 |
| New patient visit (45+ min) | 18 | $2,541 | $141 |
| Administration of additional new drug or substance into vein using push technique | 12 | $2,246 | $61 |
| Infusion into a vein for hydration, 31-60 minutes | 27 | $2,149 | $38 |
| Irrigation of implanted venous access drug delivery device | 32 | $1,927 | $25 |
| Insertion of needle into vein for collection of blood sample | 332 | $1,864 | $3 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 16 | $1,246 | $66 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 12 | $1,199 | $30 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 14 | $1,183 | $22 |
| Injection, carboplatin, 50 mg | 13 | $884 | None |
| Application of on-body injector for under skin injection | 15 | $750 | $20 |
| Infusion into a vein for hydration, each additional hour | 32 | $665 | $14 |
| Injection, ranitidine hydrochloride, 25 mg | 24 | $522 | None |
| Complete blood cell count (red cells, white blood cell, platelets), automated test | 30 | $373 | $7 |
| Injection, dexamethasone sodium phosphate, 1 mg | 98 | $250 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 49 | $224 | None |
| Infusion, normal saline solution , 1000 cc | 34 | $125 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 37 | $63 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 20 | $59 | None |
2018: 43 services
| Injection, pembrolizumab, 1 mg | 13 | $437,599 | None |
| Injection, denosumab, 1 mg | 55 | $231,114 | None |
| Injection, pegfilgrastim, 6 mg | 18 | $210,269 | None |
| Injection, rituximab, 100 mg | 13 | $176,382 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 51 | $162,983 | None |
| Return visit (30+ min) | 477 | $151,366 | $93 |
| Administration of chemotherapy into vein, 1 hour or less | 65 | $49,938 | $144 |
| Injection, ferric carboxymaltose, 1 mg | 45 | $48,526 | None |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 154 | $34,206 | $180 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 136 | $33,999 | $93 |
| Injection, palonosetron hcl, 25 mcg | 40 | $31,956 | None |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 38 | $27,650 | $1 |
| New patient visit (60+ min) | 147 | $26,565 | $181 |
| Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | 15 | $25,875 | None |
| Long return visit (40+ min) | 136 | $24,943 | $129 |
| Short return visit (20+ min) | 162 | $23,377 | $66 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 473 | $17,740 | $9 |
| Injection of drug or substance under skin or into muscle | 157 | $13,262 | $19 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 65 | $11,176 | $31 |
| Injection of additional new drug or substance into vein | 116 | $9,575 | $18 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 58 | $9,571 | $73 |
| Administration of additional new drug or substance into vein using push technique | 19 | $7,695 | $60 |
| Administration of additional new drug or substance into vein, 1 hour or less | 24 | $6,809 | $69 |
| Injection of drug or substance into vein | 74 | $5,429 | $47 |
| Infusion into a vein for hydration, 31-60 minutes | 41 | $4,913 | $47 |
| Administration of chemotherapy into vein, each additional hour | 29 | $4,568 | $31 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 41 | $3,428 | $65 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 12 | $2,110 | None |
| Injection, alteplase recombinant, 1 mg | 11 | $2,027 | None |
| Irrigation of implanted venous access drug delivery device | 33 | $1,898 | $26 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 13 | $1,625 | $22 |
| Infusion into a vein for hydration, each additional hour | 35 | $1,548 | $14 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 14 | $1,392 | $30 |
| Injection, carboplatin, 50 mg | 13 | $1,010 | None |
| Injection, ranitidine hydrochloride, 25 mg | 29 | $783 | None |
| Application of on-body injector for under skin injection | 17 | $762 | $20 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 14 | $453 | $21 |
| Injection, dexamethasone sodium phosphate, 1 mg | 119 | $367 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 51 | $340 | None |
| Infusion, normal saline solution , 1000 cc | 46 | $248 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 41 | $80 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 20 | $24 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 12 | $13 | None |
2017: 40 services
| Injection, pegfilgrastim, 6 mg | 20 | $201,453 | None |
| Injection, denosumab, 1 mg | 45 | $174,076 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 37 | $152,094 | None |
| Return visit (30+ min) | 406 | $145,541 | $93 |
| Administration of chemotherapy into vein, 1 hour or less | 60 | $41,048 | $137 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 146 | $39,741 | $90 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 164 | $36,553 | $177 |
| Injection, ferric carboxymaltose, 1 mg | 37 | $34,625 | None |
| Injection, palonosetron hcl, 25 mcg | 43 | $28,740 | None |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 38 | $27,964 | $1 |
| Long return visit (40+ min) | 122 | $22,008 | $129 |
| Short return visit (20+ min) | 145 | $21,516 | $64 |
| New patient visit (60+ min) | 113 | $20,151 | $178 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 417 | $19,587 | $10 |
| Injection, levoleucovorin, not otherwise specified, 0.5 mg | 14 | $16,471 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 73 | $14,800 | $30 |
| Injection of drug or substance under skin or into muscle | 130 | $14,320 | $24 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 73 | $11,146 | $67 |
| Infusion into a vein for hydration, 31-60 minutes | 45 | $8,690 | $57 |
| Injection of additional new drug or substance into vein | 98 | $8,133 | $22 |
| Administration of prolonged chemotherapy into vein | 12 | $7,558 | $140 |
| Administration of additional new drug or substance into vein, 1 hour or less | 22 | $5,172 | $65 |
| Administration of chemotherapy into vein, each additional hour | 30 | $4,333 | $27 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 50 | $4,111 | $63 |
| Drawing of blood for a medical problem | 11 | $3,832 | $101 |
| Administration of additional new drug or substance into vein using push technique | 16 | $3,304 | $61 |
| Injection of drug or substance into vein | 38 | $2,768 | $56 |
| Infusion into a vein for hydration, each additional hour | 35 | $2,403 | $15 |
| New patient visit (45+ min) | 15 | $2,217 | $148 |
| Irrigation of implanted venous access drug delivery device | 22 | $1,653 | $23 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 19 | $1,628 | $18 |
| Injection, carboplatin, 50 mg | 17 | $1,396 | None |
| Injection, fluorouracil, 500 mg | 16 | $1,045 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 45 | $432 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 110 | $326 | None |
| Insertion of needle into vein for collection of blood sample | 92 | $309 | $3 |
| Infusion, normal saline solution , 1000 cc | 43 | $281 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 41 | $87 | None |
| Not otherwise classified, antineoplastic drugs | 27 | $58 | None |
| Injection, magnesium sulfate, per 500 mg | 11 | $51 | None |
2016: 48 services
| Injection, pegfilgrastim, 6 mg | 19 | $187,076 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 35 | $182,163 | None |
| Injection, denosumab, 1 mg | 51 | $161,871 | None |
| Return visit (30+ min) | 400 | $142,551 | $92 |
| Not otherwise classified, antineoplastic drugs | 11 | $102,424 | None |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 79 | $59,031 | $1 |
| Administration of chemotherapy into vein, 1 hour or less | 64 | $57,630 | $130 |
| Injection, palonosetron hcl, 25 mcg | 50 | $44,964 | None |
| Short return visit (20+ min) | 212 | $36,145 | $63 |
| Injection, levoleucovorin, not otherwise specified, 0.5 mg | 11 | $36,014 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 145 | $34,235 | $88 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 103 | $24,425 | $29 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 129 | $23,173 | $170 |
| Long return visit (40+ min) | 117 | $21,263 | $120 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 377 | $20,089 | $10 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 101 | $19,488 | $66 |
| Injection, ferric carboxymaltose, 1 mg | 17 | $18,540 | None |
| New patient visit (60+ min) | 90 | $15,640 | $174 |
| Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | 16 | $15,312 | None |
| Injection of drug or substance under skin or into muscle | 108 | $13,149 | $23 |
| Administration of prolonged chemotherapy into vein | 11 | $11,079 | $135 |
| Injection of additional new drug or substance into vein | 107 | $9,045 | $21 |
| Administration of additional new drug or substance into vein, 1 hour or less | 30 | $8,785 | $60 |
| Injection, fosaprepitant, 1 mg | 11 | $7,278 | None |
| Infusion into a vein for hydration, 31-60 minutes | 38 | $6,567 | $54 |
| Administration of chemotherapy into vein, each additional hour | 34 | $6,565 | $27 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 47 | $5,979 | $69 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 50 | $4,650 | $62 |
| Administration of additional new drug or substance into vein using push technique | 13 | $4,012 | $60 |
| New patient visit (45+ min) | 23 | $3,215 | $140 |
| Infusion into a vein for hydration, each additional hour | 33 | $2,253 | $14 |
| Injection of drug or substance into vein | 27 | $2,187 | $53 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 23 | $2,172 | $17 |
| Injection, carboplatin, 50 mg | 19 | $2,059 | None |
| Irrigation of implanted venous access drug delivery device | 16 | $1,485 | $23 |
| Injection, fluorouracil, 500 mg | 13 | $1,354 | None |
| Insertion of needle into vein for collection of blood sample | 143 | $653 | $3 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 40 | $608 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 122 | $530 | None |
| Infusion, normal saline solution , 1000 cc | 42 | $291 | None |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 14 | $288 | None |
| Injection, ranitidine hydrochloride, 25 mg | 29 | $208 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 50 | $114 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 31 | $60 | None |
| Injection, magnesium sulfate, per 500 mg | 13 | $34 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 11 | $22 | None |
| Unclassified drugs | 13 | $12 | None |
| Infusion, normal saline solution, 250 cc | 11 | $5 | None |
2015: 45 services
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 44 | $230,643 | None |
| Injection, pegfilgrastim, 6 mg | 23 | $203,115 | None |
| Injection, rituximab, 100 mg | 11 | $167,870 | None |
| Injection, denosumab, 1 mg | 40 | $149,431 | None |
| Return visit (30+ min) | 329 | $146,708 | $93 |
| Administration of chemotherapy into vein, 1 hour or less | 65 | $71,310 | $131 |
| Injection, levoleucovorin, not otherwise specified, 0.5 mg | 11 | $66,593 | None |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 69 | $50,813 | $1 |
| Injection, palonosetron hcl, 25 mcg | 51 | $48,249 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 158 | $39,382 | $89 |
| Short return visit (20+ min) | 163 | $26,854 | $63 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 73 | $26,682 | $29 |
| Long return visit (40+ min) | 126 | $24,017 | $125 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 299 | $20,035 | $10 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 117 | $19,900 | $170 |
| New patient visit (60+ min) | 107 | $19,060 | $178 |
| Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | 11 | $16,864 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 80 | $16,301 | $67 |
| Injection, docetaxel, 1 mg | 12 | $13,637 | None |
| Injection of drug or substance under skin or into muscle | 84 | $12,436 | $24 |
| Injection, fosaprepitant, 1 mg | 13 | $12,087 | None |
| Administration of additional new drug or substance into vein, 1 hour or less | 35 | $10,706 | $60 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 41 | $9,130 | $72 |
| Injection of additional new drug or substance into vein | 63 | $8,630 | $21 |
| Administration of additional new drug or substance into vein using push technique | 23 | $8,557 | $60 |
| Infusion into a vein for hydration, 31-60 minutes | 43 | $5,911 | $55 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 59 | $5,880 | $62 |
| Administration of chemotherapy into vein, each additional hour | 32 | $4,777 | $27 |
| Injection of drug or substance into vein | 35 | $4,061 | $55 |
| Administration of chemotherapy into vein using push technique | 12 | $3,012 | $108 |
| Injection, carboplatin, 50 mg | 22 | $2,204 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 18 | $2,175 | $18 |
| Irrigation of implanted venous access drug delivery device | 22 | $1,928 | $22 |
| Infusion into a vein for hydration, each additional hour | 36 | $1,841 | $14 |
| Injection, fluorouracil, 500 mg | 11 | $1,758 | None |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 11 | $813 | $19 |
| Injection, dexamethasone sodium phosphate, 1 mg | 69 | $599 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 37 | $416 | None |
| Insertion of needle into vein for collection of blood sample | 81 | $356 | $3 |
| Injection, ranitidine hydrochloride, 25 mg | 36 | $285 | None |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 11 | $256 | None |
| Infusion, normal saline solution , 1000 cc | 48 | $218 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 54 | $141 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 31 | $56 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 13 | $12 | None |
2014: 48 services
| Injection, pegfilgrastim, 6 mg | 25 | $192,801 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 43 | $181,374 | None |
| Injection, denosumab, 1 mg | 25 | $117,635 | None |
| Return visit (30+ min) | 251 | $99,324 | $93 |
| Administration of chemotherapy into vein, 1 hour or less | 60 | $54,794 | $128 |
| Injection, levoleucovorin, not otherwise specified, 0.5 mg | 11 | $39,919 | None |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 54 | $39,747 | $1 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 138 | $38,174 | $89 |
| Injection, palonosetron hcl, 25 mcg | 48 | $37,179 | None |
| Injection, docetaxel, 1 mg | 18 | $28,702 | None |
| Long return visit (40+ min) | 119 | $24,648 | $123 |
| Injection, zoledronic acid, 1 mg | 15 | $17,173 | None |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 238 | $16,120 | $10 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 69 | $15,245 | $28 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 83 | $15,038 | $173 |
| Short return visit (20+ min) | 121 | $12,240 | $59 |
| New patient visit (60+ min) | 66 | $11,690 | $177 |
| Injection of additional new drug or substance into vein | 63 | $10,919 | $21 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 44 | $9,911 | $65 |
| Administration of additional new drug or substance into vein, 1 hour or less | 36 | $8,770 | $59 |
| Injection of drug or substance under skin or into muscle | 76 | $8,045 | $23 |
| Injection of drug or substance into vein | 58 | $7,260 | $54 |
| Administration of chemotherapy into vein using push technique | 24 | $5,876 | $105 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 23 | $4,808 | $71 |
| Administration of additional new drug or substance into vein using push technique | 30 | $4,513 | $59 |
| Administration of chemotherapy into vein, each additional hour | 31 | $3,993 | $26 |
| Infusion into a vein for hydration, 31-60 minutes | 21 | $3,827 | $52 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 30 | $3,156 | $62 |
| Injection, carboplatin, 50 mg | 26 | $2,115 | None |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 13 | $2,064 | None |
| Irrigation of implanted venous access drug delivery device | 21 | $1,798 | $23 |
| Infusion into a vein for hydration, each additional hour | 24 | $1,397 | $14 |
| Blood test, comprehensive group of blood chemicals | 67 | $1,392 | $13 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 13 | $1,252 | $17 |
| New patient visit (30+ min) | 14 | $1,247 | $89 |
| Injection, fluorouracil, 500 mg | 12 | $990 | None |
| Carcinoembryonic antigen (cea) protein level | 15 | $659 | $25 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 18 | $501 | $19 |
| Injection, dexamethasone sodium phosphate, 1 mg | 54 | $376 | None |
| Insertion of needle into vein for collection of blood sample | 74 | $315 | $3 |
| Ferritin (blood protein) level | 16 | $310 | $18 |
| Injection, ranitidine hydrochloride, 25 mg | 29 | $196 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 58 | $131 | None |
| Infusion, normal saline solution , 1000 cc | 34 | $127 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 22 | $125 | None |
| Iron level | 12 | $112 | $9 |
| Injection, ondansetron hydrochloride, per 1 mg | 19 | $23 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 15 | $12 | None |
2013: 48 services
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 31 | $138,287 | None |
| Return visit (30+ min) | 256 | $84,340 | $89 |
| Injection, pegfilgrastim, 6 mg | 16 | $81,426 | None |
| Administration of chemotherapy into vein, 1 hour or less | 57 | $64,765 | $136 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 157 | $38,932 | $86 |
| Injection, palonosetron hcl, 25 mcg | 49 | $38,656 | None |
| Injection, docetaxel, 1 mg | 15 | $27,319 | None |
| Injection, filgrastim (g-csf), 480 mcg | 15 | $25,434 | None |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 114 | $20,094 | $167 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 28 | $17,897 | $1 |
| Administration of additional new drug or substance into vein, 1 hour or less | 40 | $16,797 | $67 |
| Zoldedronic acid 1mg | 11 | $15,940 | $134 |
| Long return visit (40+ min) | 78 | $15,790 | $122 |
| Short return visit (20+ min) | 128 | $14,245 | $60 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 223 | $13,695 | $11 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 61 | $13,462 | $30 |
| New patient visit (60+ min) | 63 | $10,880 | $173 |
| Injection, oxaliplatin, 0.5 mg | 11 | $8,615 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 43 | $7,904 | $72 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 21 | $7,892 | None |
| Administration of chemotherapy into vein using push technique | 31 | $6,827 | $107 |
| Injection of drug or substance under skin or into muscle | 56 | $5,880 | $23 |
| Blood test, comprehensive group of blood chemicals | 140 | $5,535 | $14 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 55 | $5,095 | $60 |
| Administration of chemotherapy into vein, each additional hour | 35 | $3,854 | $29 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 47 | $3,411 | $17 |
| Carcinoembryonic antigen (cea) protein level | 37 | $3,002 | $26 |
| Injection of additional new drug or substance into vein | 34 | $2,125 | $21 |
| Biopsy of bone marrow | 13 | $1,901 | $146 |
| Injection, carboplatin, 50 mg | 26 | $1,877 | None |
| Administration of additional new drug or substance into vein using push technique | 11 | $1,359 | $59 |
| Aspiration of bone marrow sample for diagnosis | 14 | $1,150 | $82 |
| Ferritin (blood protein) level | 38 | $1,052 | $18 |
| Irrigation of implanted venous access drug delivery device | 18 | $961 | $23 |
| Psa (prostate specific antigen) measurement, total | 11 | $775 | $25 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 15 | $723 | $20 |
| Cyanocobalamin (vitamin b-12) level | 26 | $531 | $20 |
| Injection, granisetron hydrochloride, 100 mcg | 18 | $422 | None |
| Iron binding capacity | 34 | $417 | $9 |
| Iron level | 34 | $403 | $9 |
| Folic acid level, serum | 18 | $399 | $20 |
| Injection, dexamethasone sodium phosphate, 1 mg | 60 | $370 | None |
| Lactate dehydrogenase (enzyme) level | 21 | $274 | $7 |
| Injection, ranitidine hydrochloride, 25 mg | 26 | $155 | None |
| Infusion, normal saline solution , 1000 cc | 38 | $141 | None |
| Insertion of needle into vein for collection of blood sample | 37 | $121 | $3 |
| Injection, diphenhydramine hcl, up to 50 mg | 49 | $117 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 11 | $70 | None |
Medicaid work
$34,458 in 2024
Medicaid paid $34,458 for 669 billed services this clinician did in 2024, up to 41 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 393 | $28,154 |
| Short return visit (20+ min) | 66 | $3,713 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 183 | $1,488 |
| Long return visit (40+ min) | 13 | $933 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 14 | $170 |
| 2024 | 669 | 5 | 41 | $34,458 |
| 2023 | 842 | 4 | 41 | $33,320 |
| 2022 | 783 | 4 | 36 | $27,414 |
| 2021 | 1,235 | 4 | 40 | $39,288 |
| 2020 | 2,349 | 10 | 65 | $67,765 |
| 2019 | 2,214 | 11 | 49 | $73,815 |
| 2018 | 2,557 | 12 | 62 | $75,965 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 356 | $24,852 |
| Short return visit (20+ min) | 122 | $5,767 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 337 | $2,459 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 27 | $242 |
2022
| Return visit (30+ min) | 307 | $20,088 |
| Short return visit (20+ min) | 73 | $5,072 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 364 | $2,009 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 39 | $245 |
2021
| Return visit (30+ min) | 328 | $24,751 |
| Short return visit (20+ min) | 195 | $9,703 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 442 | $3,053 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 270 | $1,782 |
2020
| Return visit (30+ min) | 689 | $37,874 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 255 | $14,966 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 586 | $3,953 |
| Short return visit (20+ min) | 72 | $3,271 |
| Injection, dexamethasone sodium phosphate, 1 mg | 108 | $2,932 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure) | 139 | $2,636 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 300 | $2,054 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 25 | $79 |
| Advance Care Planning discussed and documented advance care plan or surrogate decision maker documented in the medical record (DEM) (GER, Pall Cr) | 130 | $0 |
| COLLECTION VENOUS BLOOD VENIPUNCTURE | 45 | $0 |
2019
| Return visit (30+ min) | 546 | $37,201 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 113 | $7,903 |
| Injection, dexamethasone sodium phosphate, 1 mg | 289 | $7,323 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 541 | $4,998 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure) | 240 | $4,647 |
| Palonosetron hcl | 23 | $3,500 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 327 | $3,285 |
| Short return visit (20+ min) | 65 | $3,123 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 24 | $1,227 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure) | 15 | $492 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 31 | $117 |
2018
| Denosumab injection | 24 | $33,057 |
| Return visit (30+ min) | 606 | $17,756 |
| Injection, dexamethasone sodium phosphate, 1 mg | 334 | $8,642 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 412 | $4,025 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 607 | $2,883 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure) | 197 | $2,639 |
| Short return visit (20+ min) | 117 | $2,116 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure) | 73 | $1,854 |
| Palonosetron hcl | 17 | $1,635 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 66 | $988 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 89 | $355 |
| Injection, diphenhydramine hcl, up to 50 mg | 15 | $16 |
Drugs they prescribed that Part D paid
$423,051
Pharmacies billed $423,051 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 596) in 2024. At or below the middle of the specialty; the typical hematology clinician is at 4%.
459 generic and 137 brand-name prescriptions · $423,051 in drug cost · 23 antibiotic prescriptions to 20 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 74 | $72,304 | $977 |
| Xarelto | 37 | $40,128 | $1,085 |
| Tamoxifen Citrate | 90 | $2,614 | $29 |
| Mirtazapine | 63 | $1,056 | $17 |
| Letrozole | 33 | $718 | $22 |
See all 10 drugs
| Eliquis | 74 | $72,304 | $977 |
| Xarelto | 37 | $40,128 | $1,085 |
| Tamoxifen Citrate | 90 | $2,614 | $29 |
| Mirtazapine | 63 | $1,056 | $17 |
| Letrozole | 33 | $718 | $22 |
| Gabapentin | 53 | $714 | $13 |
| Hydroxyurea | 28 | $428 | $15 |
| Prednisone | 23 | $148 | $6 |
| Lactulose | 12 | $110 | $9 |
| Alendronate | 26 | $83 | $3 |
Year by year
| 2024 | 596 | 226 | 0% (0) | 23% | $423,051 |
| 2023 | 572 | 199 | None | 15% | $509,177 |
| 2022 | 564 | 205 | 5% (26) | 19% | $924,142 |
| 2021 | 690 | 223 | 9% (65) | 25% | $1,079,590 |
| 2020 | 668 | 214 | 8% (52) | None | $803,208 |
| 2019 | 1,376 | 247 | 7% (93) | None | $2,196,729 |
| 2018 | 1,262 | 245 | 4% (49) | 19% | $1,868,144 |
| 2017 | 1,156 | 229 | 7% (76) | 14% | $1,194,707 |
| 2016 | 1,474 | 241 | 9% (137) | 17% | $1,770,198 |
| 2015 | 1,181 | 200 | 8% (89) | 16% | $1,131,974 |
| 2014 | 1,335 | 172 | 13% (175) | 15% | $535,789 |
| 2013 | 1,460 | 186 | 11% (164) | None | $812,786 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 9 drugs
| Eliquis | 45 | $38,663 | $859 |
| Xarelto | 12 | $15,415 | $1,285 |
| Tamoxifen Citrate | 80 | $2,324 | $29 |
| Mirtazapine | 72 | $2,041 | $28 |
| Gabapentin | 77 | $1,290 | $17 |
| Hydroxyurea | 20 | $818 | $41 |
| Letrozole | 27 | $754 | $28 |
| Alendronate | 22 | $254 | $12 |
| Prednisone | 31 | $235 | $8 |
2022: 12 drugs
| Imbruvica | 16 | $243,587 | $15,224 |
| Eliquis | 26 | $32,222 | $1,239 |
| Xarelto | 13 | $8,351 | $642 |
| Tamoxifen Citrate | 77 | $2,681 | $35 |
| Mirtazapine | 25 | $820 | $33 |
| Letrozole | 30 | $750 | $25 |
| Gabapentin | 42 | $590 | $14 |
| Hydroxyurea | 14 | $471 | $34 |
| Dexamethasone | 15 | $328 | $22 |
| Prednisone | 39 | $223 | $6 |
| Prochlorperazine Maleate | 11 | $182 | $17 |
| Hydrocodone-Acetaminophen | 11 | $171 | $16 |
2021: 15 drugs
| Xtandi | 18 | $215,031 | $11,946 |
| Imbruvica | 12 | $135,900 | $11,325 |
| Eliquis | 61 | $42,856 | $703 |
| Xarelto | 16 | $15,023 | $939 |
| Tamoxifen Citrate | 65 | $3,103 | $48 |
| Anastrozole | 22 | $1,145 | $52 |
| Gabapentin | 61 | $927 | $15 |
| Hydroxyurea | 13 | $569 | $44 |
| Megestrol Acetate | 13 | $461 | $35 |
| Letrozole | 27 | $389 | $14 |
| Alendronate | 23 | $341 | $15 |
| Hydrocodone-Acetaminophen | 25 | $324 | $13 |
| Ondansetron Odt | 11 | $261 | $24 |
| Dexamethasone | 17 | $190 | $11 |
| Prednisone | 39 | $185 | $5 |
2020: 19 drugs
| Zejula | 12 | $93,204 | $7,767 |
| Imatinib Mesylate | 14 | $51,880 | $3,706 |
| Erlotinib | 12 | $33,481 | $2,790 |
| Eliquis | 55 | $29,881 | $543 |
| Xarelto | 15 | $13,042 | $869 |
| Tamoxifen Citrate | 53 | $3,020 | $57 |
| Anastrozole | 45 | $1,565 | $35 |
| Morphine Sulfate Er | 15 | $672 | $45 |
| Hydroxyurea | 16 | $553 | $35 |
| Gabapentin | 31 | $476 | $15 |
| Letrozole | 21 | $463 | $22 |
| Ondansetron Odt | 18 | $447 | $25 |
| Mirtazapine | 16 | $432 | $27 |
| Dexamethasone | 17 | $356 | $21 |
| Alendronate | 23 | $315 | $14 |
| Prednisone | 27 | $180 | $7 |
| Hydrocodone-Acetaminophen | 17 | $137 | $8 |
| Prochlorperazine Maleate | 11 | $117 | $11 |
| Lorazepam | 14 | $48 | $3 |
2019: 36 drugs
| Revlimid | 21 | $366,735 | $17,464 |
| Jakafi | 32 | $362,930 | $11,342 |
| Zytiga | 32 | $292,035 | $9,126 |
| Stivarga | 12 | $189,404 | $15,784 |
| Imbruvica | 13 | $162,546 | $12,504 |
| Votrient | 12 | $153,523 | $12,794 |
| Sutent | 13 | $122,336 | $9,410 |
| Imatinib Mesylate | 22 | $102,501 | $4,659 |
| Zejula | 12 | $87,004 | $7,250 |
| Eliquis | 62 | $42,298 | $682 |
| Promacta | 11 | $23,385 | $2,126 |
| Xarelto | 29 | $20,842 | $719 |
| Tamoxifen Citrate | 134 | $5,410 | $40 |
| Gabapentin | 114 | $1,665 | $15 |
| Letrozole | 92 | $1,564 | $17 |
| Anastrozole | 39 | $1,346 | $35 |
| Acyclovir | 24 | $1,285 | $54 |
| Hydroxyurea | 41 | $1,207 | $29 |
| Morphine Sulfate Er | 20 | $1,117 | $56 |
| Mirtazapine | 30 | $739 | $25 |
| Prednisone | 80 | $511 | $6 |
| Diphenoxylate-Atropine | 18 | $501 | $28 |
| Hydrocodone-Acetaminophen | 28 | $476 | $17 |
| Oxycodone-Acetaminophen | 17 | $396 | $23 |
| Ondansetron Odt | 12 | $356 | $30 |
| Megestrol Acetate | 18 | $335 | $19 |
| Dexamethasone | 17 | $325 | $19 |
| Prochlorperazine Maleate | 30 | $284 | $9 |
| Alendronate | 37 | $263 | $7 |
| Pantoprazole | 16 | $237 | $15 |
| Ondansetron | 26 | $227 | $9 |
| Lorazepam | 26 | $110 | $4 |
| Metoclopramide | 12 | $104 | $9 |
| Sertraline | 13 | $88 | $7 |
| Cephalexin | 12 | $60 | $5 |
| Hydrochlorothiazide | 20 | $37 | $2 |
2018: 33 drugs
| Imatinib Mesylate | 29 | $222,846 | $7,684 |
| Votrient | 19 | $215,135 | $11,323 |
| Zejula | 18 | $213,030 | $11,835 |
| Gleevec | 21 | $140,001 | $6,667 |
| Jakafi | 11 | $137,112 | $12,465 |
| Sutent | 12 | $122,372 | $10,198 |
| Jadenu | 13 | $114,272 | $8,790 |
| Ibrance | 11 | $110,483 | $10,044 |
| Eliquis | 38 | $25,420 | $669 |
| Xarelto | 21 | $8,795 | $419 |
| Tamoxifen Citrate | 128 | $4,772 | $37 |
| Megestrol Acetate | 15 | $3,502 | $233 |
| Acyclovir | 13 | $1,814 | $140 |
| Hydroxyurea | 58 | $1,411 | $24 |
| Letrozole | 116 | $1,192 | $10 |
| Gabapentin | 93 | $947 | $10 |
| Bicalutamide | 25 | $724 | $29 |
| Anastrozole | 37 | $687 | $19 |
| Hydrocodone-Acetaminophen | 26 | $597 | $23 |
| Mirtazapine | 33 | $454 | $14 |
| Prednisone | 65 | $366 | $6 |
| Diphenoxylate-Atropine | 17 | $352 | $21 |
| Ondansetron Odt | 27 | $351 | $13 |
| Prochlorperazine Maleate | 34 | $285 | $8 |
| Sertraline | 15 | $160 | $11 |
| Lorazepam | 37 | $145 | $4 |
| Pantoprazole | 12 | $136 | $11 |
| Venlafaxine Hcl Er | 11 | $122 | $11 |
| Alendronate | 19 | $119 | $6 |
| Levetiracetam | 12 | $104 | $9 |
| Metoclopramide | 13 | $64 | $5 |
| Hydrochlorothiazide | 12 | $51 | $4 |
| Cephalexin | 12 | $50 | $4 |
2017: 25 drugs
| Gleevec | 11 | $178,848 | $16,259 |
| Xtandi | 16 | $162,190 | $10,137 |
| Imatinib Mesylate | 18 | $152,273 | $8,460 |
| Gilotrif | 12 | $95,647 | $7,971 |
| Eliquis | 29 | $16,266 | $561 |
| Tamoxifen Citrate | 111 | $3,598 | $32 |
| Hydroxyurea | 61 | $1,303 | $21 |
| Letrozole | 92 | $1,128 | $12 |
| Anastrozole | 51 | $932 | $18 |
| Megestrol Acetate | 31 | $895 | $29 |
| Hydrocodone-Acetaminophen | 54 | $813 | $15 |
| Mirtazapine | 40 | $712 | $18 |
| Gabapentin | 86 | $678 | $8 |
| Bicalutamide | 21 | $456 | $22 |
| Dexamethasone | 15 | $388 | $26 |
| Warfarin | 33 | $301 | $9 |
| Ondansetron Odt | 21 | $292 | $14 |
| Lorazepam | 49 | $249 | $5 |
| Prednisone | 33 | $210 | $6 |
| Acyclovir | 17 | $173 | $10 |
| Venlafaxine Hcl Er | 26 | $170 | $7 |
| Prochlorperazine Maleate | 22 | $164 | $7 |
| Levetiracetam | 16 | $154 | $10 |
| Sertraline | 23 | $87 | $4 |
| Cephalexin | 12 | $46 | $4 |
2016: 36 drugs
| Revlimid | 28 | $360,312 | $12,868 |
| Xtandi | 34 | $304,893 | $8,967 |
| Ibrance | 22 | $230,184 | $10,463 |
| Xalkori | 13 | $188,951 | $14,535 |
| Imatinib Mesylate | 20 | $176,056 | $8,803 |
| Tarceva | 20 | $106,949 | $5,347 |
| Promacta | 11 | $53,547 | $4,868 |
| Xarelto | 32 | $11,437 | $357 |
| Advair Diskus | 12 | $4,101 | $342 |
| Tamoxifen Citrate | 151 | $3,574 | $24 |
| Hydrocodone-Acetaminophen | 72 | $1,840 | $26 |
| Hydroxyurea | 58 | $1,399 | $24 |
| Letrozole | 91 | $1,041 | $11 |
| Morphine Sulfate Er | 19 | $738 | $39 |
| Gabapentin | 78 | $714 | $9 |
| Megestrol Acetate | 33 | $679 | $21 |
| Oxycodone-Acetaminophen | 12 | $572 | $48 |
| Warfarin | 25 | $478 | $19 |
| Anastrozole | 52 | $461 | $9 |
| Acyclovir | 27 | $451 | $17 |
| Lidocaine-Prilocaine | 13 | $391 | $30 |
| Mirtazapine | 40 | $386 | $10 |
| Prednisone | 65 | $368 | $6 |
| Ondansetron Odt | 18 | $301 | $17 |
| Lorazepam | 59 | $297 | $5 |
| Doxycycline Monohydrate | 11 | $293 | $27 |
| Prochlorperazine Maleate | 50 | $281 | $6 |
| Levetiracetam | 18 | $243 | $14 |
| Dexamethasone | 22 | $233 | $11 |
| Diphenoxylate-Atropine | 11 | $201 | $18 |
| Ondansetron | 15 | $200 | $13 |
| Metoclopramide | 16 | $104 | $7 |
| Pantoprazole | 12 | $97 | $8 |
| Venlafaxine Hcl Er | 16 | $97 | $6 |
| Sertraline | 13 | $68 | $5 |
| Metoprolol | 16 | $64 | $4 |
2015: 28 drugs
| Xalkori | 19 | $256,892 | $13,521 |
| Xtandi | 25 | $218,865 | $8,755 |
| Revlimid | 12 | $156,109 | $13,009 |
| Votrient | 12 | $103,377 | $8,615 |
| Tarceva | 17 | $90,340 | $5,314 |
| Tamoxifen Citrate | 108 | $3,096 | $29 |
| Hydroxyurea | 64 | $1,176 | $18 |
| Gabapentin | 91 | $897 | $10 |
| Hydrocodone-Acetaminophen | 41 | $805 | $20 |
| Letrozole | 93 | $778 | $8 |
| Anastrozole | 42 | $655 | $16 |
| Megestrol Acetate | 25 | $409 | $16 |
| Prednisone | 66 | $383 | $6 |
| Mirtazapine | 44 | $376 | $9 |
| Warfarin | 19 | $358 | $19 |
| Prochlorperazine Maleate | 33 | $230 | $7 |
| Lorazepam | 47 | $202 | $4 |
| Venlafaxine | 13 | $193 | $15 |
| Pantoprazole | 19 | $148 | $8 |
| Hydromorphone | 14 | $141 | $10 |
| Dexamethasone | 12 | $115 | $10 |
| Acyclovir | 12 | $110 | $9 |
| Alendronate | 16 | $98 | $6 |
| Lactulose | 14 | $82 | $6 |
| Omeprazole | 13 | $76 | $6 |
| Terazosin | 12 | $54 | $5 |
| Sertraline | 13 | $50 | $4 |
| Furosemide | 13 | $31 | $2 |
2014: 33 drugs
| Revlimid | 13 | $149,248 | $11,481 |
| Gleevec | 12 | $99,272 | $8,273 |
| Tarceva | 17 | $96,252 | $5,662 |
| Procrit | 12 | $10,154 | $846 |
| Xarelto | 24 | $6,652 | $277 |
| Fentanyl | 29 | $3,507 | $121 |
| Tamoxifen Citrate | 128 | $3,369 | $26 |
| Anastrozole | 78 | $1,906 | $24 |
| Hydrocodone-Acetaminophen | 63 | $1,357 | $22 |
| Letrozole | 42 | $858 | $20 |
| Megestrol Acetate | 32 | $786 | $25 |
| Warfarin | 59 | $754 | $13 |
| Gabapentin | 62 | $719 | $12 |
| Hydroxyurea | 20 | $561 | $28 |
| Morphine Sulfate Er | 11 | $496 | $45 |
| Ondansetron Odt | 17 | $460 | $27 |
| Hydromorphone | 29 | $439 | $15 |
| Pantoprazole | 40 | $410 | $10 |
| Acyclovir | 20 | $365 | $18 |
| Prednisone | 67 | $364 | $5 |
| Ondansetron | 28 | $312 | $11 |
| Lidocaine-Prilocaine | 12 | $280 | $23 |
| Oxycodone-Acetaminophen | 11 | $230 | $21 |
| Prochlorperazine Maleate | 35 | $217 | $6 |
| Sertraline | 28 | $201 | $7 |
| Lorazepam | 39 | $195 | $5 |
| Mirtazapine | 24 | $187 | $8 |
| Dexamethasone | 17 | $185 | $11 |
| Zolpidem | 20 | $163 | $8 |
| Levofloxacin | 12 | $129 | $11 |
| Levothyroxine | 12 | $55 | $5 |
| Alprazolam | 11 | $52 | $5 |
| Furosemide | 15 | $42 | $3 |
2013: 32 drugs
| Revlimid | 44 | $475,482 | $10,806 |
| Gleevec | 24 | $160,658 | $6,694 |
| Aranesp | 14 | $44,575 | $3,184 |
| Anastrozole | 105 | $3,308 | $32 |
| Tamoxifen Citrate | 113 | $2,084 | $18 |
| Fentanyl | 16 | $1,659 | $104 |
| Ondansetron | 21 | $1,649 | $79 |
| Letrozole | 37 | $1,564 | $42 |
| Hydroxyurea | 34 | $1,423 | $42 |
| Warfarin | 75 | $1,115 | $15 |
| Gabapentin | 64 | $905 | $14 |
| Hydrocodone-Acetaminophen | 59 | $735 | $12 |
| Megestrol Acetate | 22 | $631 | $29 |
| Prochlorperazine Maleate | 71 | $458 | $6 |
| Hydromorphone | 26 | $405 | $16 |
| Prednisone | 95 | $351 | $4 |
| Lorazepam | 62 | $278 | $4 |
| Sertraline | 26 | $274 | $11 |
| Tamsulosin | 13 | $239 | $18 |
| Pantoprazole | 24 | $230 | $10 |
| Dexamethasone | 21 | $226 | $11 |
| Mirtazapine | 24 | $195 | $8 |
| Acetaminophen-Codeine | 23 | $172 | $7 |
| Zolpidem | 29 | $157 | $5 |
| Generlac | 18 | $150 | $8 |
| Levofloxacin | 13 | $123 | $9 |
| Omeprazole | 15 | $101 | $7 |
| Lactulose | 13 | $86 | $7 |
| Amlodipine Besylate | 17 | $85 | $5 |
| Furosemide | 25 | $79 | $3 |
| Alprazolam | 13 | $71 | $5 |
| Hydrochlorothiazide | 11 | $39 | $4 |
Money from drug and device companies
$15 in 2025
| 2025 | 1 | 1 | None | $15 |
| 2024 | 5 | 6 | None | $180 |
| 2023 | 7 | 8 | None | $290 |
| 2022 | 4 | 5 | None | $111 |
| 2021 | 5 | 15 | None | $346 |
| 2020 | 3 | 5 | $1,000 | $1,069 |
| 2019 | 4 | 5 | None | $276 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Elahere | $15 | 1 payment
|
See the published payment
| Abbvie | Meals · 2025-10-07 | Elahere | $15 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $180
| CSL Behring | Kcentra | $66 | 1 payment
|
| Celgene | Pomalyst | $51 | 2 payments
|
| Eisai | Lenvima | $24 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $22 | 1 payment
|
| Gilead Sciences | None | $18 | 1 payment
|
2023: $290
| Rigel Pharmaceuticals | Rezlidhia | $119 | 1 payment
|
| Pfizer | Ibrance | $46 | 2 payments
|
| Daiichi Sankyo | None | $28 | 1 payment
|
| Seagen | Tukysa | $27 | 1 payment
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $26 | 1 payment
|
| Novartis Pharmaceuticals | None | $24 | 1 payment
|
| Coherus Biosciences | Udenyca | $19 | 1 payment
|
2022: $111
| Seagen | Padcev | $62 | 2 payments
|
| Pfizer | None | $24 | 1 payment
|
| Coherus Biosciences | Udenyca | $13 | 1 payment
|
| Janssen Pharmaceuticals | None | $12 | 1 payment
|
2021: $346
| Pfizer | Inlyta | $255 | 10 payments
|
| Acrotech Biopharma | Beleodaq | $28 | 2 payments
|
| Seagen | Tukysa | $25 | 1 payment
|
| Genentech USA | None | $19 | 1 payment
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $19 | 1 payment
|
2020: $1,069
| Rigel Pharmaceuticals | Tavalisse | $1,000 | 1 payment
|
| Pfizer | Inlyta | $37 | 3 payments
|
| Janssen Biotech | Darzalex | $31 | 1 payment
|
2019: $276
| Merck Sharp & Dohme | Keytruda | $125 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $120 | 1 payment
|
| Pfizer | Braftovi | $24 | 2 payments
|
| Janssen Biotech | Imbruvica | $7 | 1 payment
|
Professional record
- NPI
- 1154541423
- Licence
- CA A93287, NJ 25MA08210300California A93287: Current · expires 2027-11-30New Jersey 25MA08210300: Inactive
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RH0000X (207RH0000X); Internal medicine (207R00000X); Medical oncology (207RX0202X)
- Mailing address
- 20055 Lake Chabot Rd Ste 130, Castro Valley, CA, 94546
- NPI first listed
- 2007-04-27
- NPI last updated
- 2024-08-08
- NPI record certified
- 2024-08-08
This is when the NPI record was last certified, not a medical board exam.